South Korea’s Hyundai Bioscience is preparing to start clinical trials of what it hopes could become the first antiviral ...

At last month’s Reuters Pharma USA conference in Philadelphia, pharmaphorum’s Jonah Comstock caught up with Serena Goodwin, a ...

Researchers in the US have developed an artificial intelligence tool that can predict how a patient will respond to cancer ...

Cerevel Therapeutics’ Parkinson’s disease therapy tavapadon has shown efficacy in a phase 3 trial, reinforcing its ...

Roche has broken new ground with its ALK inhibitor Alecenesa, becoming the first drug in the class to be approved by the FDA ...

Any company hoping to make headway in the market for obesity therapies will need deep pockets, so it’s an encouraging sign ...

Beckley Psytech, just months away from a readout of a phase 2b trial of its psychedelic therapy for treatment-resistant depression (TRD), has built anticipation with new data showing a rapid and ...

The QR4 algorithm, described in the journal Nature Medicine, can be thought of as a “calculator” that takes into account ...

In a new episode of the pharmaphorum podcast, web editor Nicole Raleigh welcomes Dr Carl Marci, chief psychiatrist and ...

A gene therapy for heart failure being developed by Bayer’s AskBio unit has been granted fast-track status by the FDA, ...

Ireland has made the case to build on its position within Europe’s medtech research and manufacturing sector in a new report ...

Equally crucial are contractual safeguards. Well-crafted agreements such as Non-Disclosure Agreements (NDAs) and licensing ...